Clinical Trial Update: Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two years of CP-945,598 for weight loss in obesity was terminated; the update provides information on efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-945,598 (CP-945,598)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 3 | Status: TERMINATED